Drugs / Miricorilant
Trials 14 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 110 trials | ||||||
| Phase 1 | NCT07553663 | Apr → Oct 2026 expected | NAFLD1, metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT07240116 | Sep 2025 → Mar 2026 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT06947304 | Aug 2025 → May 2026 overdue | NAFLD1, metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT05712265 | Jan → Feb 2023 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05553470 | Mar 2022 → Sep 2024 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT05117489 | Nov 2021 → Jan 2024 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT04672499 | Apr → Sep 2020 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03877562 | Apr 2019 → Mar 2020 | acquired hypothalamic obesity | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03878264 | Aug 2018 → Mar 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03315338 | Sep 2017 → Feb 2019 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT06108219 | Oct 2023 → Sep 2026 expected | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03823703 | Nov 2020 → Apr 2021 | metabolic dysfunction-associated steatohepatitis | Corcept Therapeutics | Terminated | No outcome recorded |
| Phase 2 | NCT04524403 | Sep 2020 → Jul 2022 | — | Corcept Therapeutics | Completed | No outcome recorded |
| Phase 2 | NCT03818256 | Dec 2019 → Jun 2022 | — | Corcept Therapeutics | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT04466215 Comparator | Apr 2021 → Apr 2022 | alcohol-related disorders | The Scripps Research Institute | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 16 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Miricorilant | “This study will evaluate relative bioavailability of Kinetisol and spray dried dispersion (SDD) miricorilant (CORT118335) tablets.” NCT07240116 ↗11“Miricorilant 600 mg (4 X 150 mg) for once-daily for oral dosing” NCT04524403 ↗ |
| Known as | CORT118335 | “miricorilant (CORT118335) in obese adults with schizophrenia or bipolar disorder treated with antipsychotic medications” NCT03818256 ↗ |
| Modality | Small molecule | — CHEMBL4297602 ↗ |
| Route | Oral | “CORT118335 is supplied as capsules for oral dosing” NCT03315338 ↗ |